News
Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...
It’s a bad time to try to predict future pharmaceutical prices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback